Trial Profile
A Phase Ib, Open-Label, Single Arm Study to Assess the Safety, Pharmacokinetics, and Impact on Humoral Sensitization of SANGUINATE Infusion in Patients With End-Stage Renal Disease (ESRD)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 29 May 2018
Price :
$35
*
At a glance
- Drugs PEG-haemoglobin carbon monoxide (Primary)
- Indications Renal failure
- Focus Adverse reactions
- Sponsors Prolong Pharmaceuticals
- 15 Nov 2017 Results published in the Clinical Transplantation
- 03 May 2017 Results assessing safety,pharmacokinetics and impact on humoral sensitization of SANGUINATE infusion presented at the 2017 American Transplant Congress.
- 03 May 2017 Status changed from recruiting to discontinued according to the results published at the 2017 American Transplant Congress.